2,4-Dihydro-3h-1,2,4-triazol-3-one P2X7 receptor antagonists have been reported in an Axxam SpA patent as potentially useful for the treatment of cognitive, eye, gastrointestinal, genitourinary and psychiatric disorders, chronic pain, neuropathic pain and neurodegeneration.
Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have patented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
A recent Shenzhen Salubris Pharmaceuticals Co. Ltd. patent describes prodrugs of atrasentan that act as endothelin ETA receptor antagonists. As such, they are reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, hypertension and IgA nephropathy.
Spark Biopharma Inc. has prepared and tested stimulator of interferon genes protein (STING; TMEM173) agonists that are reported to be useful for the treatment of cancer.
Mitogen-activated protein kinase kinase kinase 13 (MAP3K13; LZK) inhibitors reported to be useful for the treatment of cancer have been described in a recent U.S. Department of Health and Human Services patent.
Research at KHR Biotec GmbH has led to the development of eukaryotic initiation factor 4A (elF4A) and GTPase mutant inhibitors potentially useful for the treatment of cancer, craniofacial syndrome and neurofibromatosis type I.
(Azacycloalkyl)methoxy-substituted benzamides acting as trace amine-associated receptor 1 (TAAR1; TAR1) agonists have been described in a recent Accellena Research and Development LLC patent.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described 5-fluoro-7h-pyrrolo[2,3-d] pyrimidine compounds as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer.
RSS
